ArticleThe Journal of clinical investigation1995
Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors.
Article in The Journal of clinical investigation, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 359 citations in OpenAlex.
- Histamine-releasing factor enhances food allergy.The Journal of clinical investigation · 2017Trial
- Inhibitory Fc Receptor sets a time limit on macrophage response to IgG.bioRxiv : the preprint server for biology · 2026Article
- Multiple roads to IgE memory: A pluralistic model of IgE immunity.Cell reports · 2026Review
- Emerging Therapies for Anaphylaxis.Immunology and allergy clinics of North America · 2026Review
- Impact of cross-linking stoichiometry on the structure and allergenicity of glutaraldehyde-polymerized allergen extracts.Frontiers in immunology · 2026Article
- Subcutaneous Allergen-Specific Immunotherapy for Allergic Rhinitis: Divergent IgA Responses in Nasal Mucosa and Blood With Validation of B Cell Class-Switching in Lymph Nodes and Blood.Clinical and translational allergy · 2025Article
- Pathogenic and Nonpathogenic Antibody Responses in Allergic Diseases.European journal of immunology · 2025Review
- Life-threatening antibodies: The discovery of anaphylaxis.Immunological reviews · 2024Review
- Allergen-specific IgA and IgG antibodies as inhibitors of mast cell function in food allergy.Frontiers in allergy · 2024Review
- IgG:FcγRIIb signals block effector programs of IgE:FcεRI-activated mast cells but spare survival pathways.The Journal of allergy and clinical immunology · 2023Article
- Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis.The journal of allergy and clinical immunology. In practice · 2023Review
- Targeted Inhibition of Select Extracellular Signal-regulated Kinases 1 and 2 Functions Mitigates Pathological Features of Asthma in Mice.American journal of respiratory cell and molecular biology · 2023Article
- A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies.Frontiers in immunology · 2022Review
- The clinical significance of allergen-specific IgG4 in allergic diseases.Frontiers in immunology · 2022Review
- Allergen-Specific IgA Antibodies Block IgE-Mediated Activation of Mast Cells and Basophils.Frontiers in immunology · 2022Article
- Review
- Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic.International journal of molecular sciences · 2021Review
- FcεR1-expressing nociceptors trigger allergic airway inflammation.The Journal of allergy and clinical immunology · 2021Article
- Strategies for Mast Cell Inhibition in Food Allergy.The Yale journal of biology and medicine · 2020Review
- Targeting the FcεRI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis.Frontiers in immunology · 2020Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic symptoms result from the release of granular and lipidic mediators and of cytokines by inflammatory cells. The whole process is initiated by the aggregation of mast cell and basophil high-affinity IgE receptors (Fc epsilon RI) by IgE and antigen. We report here that IgE-induced release of mediator and cytokine can be inhibited by cross-linking Fc epsilon RI to low-affinity IgG receptors (Fc gamma RII) which are constitutively expressed on mast cells and basophils. Using a model of stable transfectants in RBL-2H3 cells expressing endogeneous rat Fc epsilon RI and recombinant murine Fc gamma RII, we showed that inhibition requires that Fc epsilon RI be crosslinked to Fc gamma RII by the same multivalent ligand. Inhibition of cross-linked receptors left non-cross-linked Fc epsilon RI capable of triggering mediator release and was reversible upon disengagement. Both isoforms of wild-type Fc gamma RII were equally capable of inhibiting Fc epsilon RI-mediated mast cell activation provided they had an intact intracytoplasmic domain. Our results demonstrate that mast cell secretory responses triggered by high-affinity receptors for IgE may be controlled by low-affinity receptors for IgG. This regulation of Fc epsilon RI-mediated mast cell activation is of potential interest in mast cell physiology and in allergic pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.